Drug class profile · refreshed daily from federal data

Opioid Agonist/Antagonist

2 molecules in this class, $3.5M combined CY2024 Part D spend across 38K claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Opioid Agonist/Antagonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $3.5Mcombined across class
Total Rx claims: 38K5K unique beneficiaries
Generic mfrs (active): 6across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Butorphanol

36K Part D claims (CY24) · 5K beneficiaries · First FDA approval: 2002-03-12

4 generic mfrs 0 plans require PA

Low NADAC$14.80

→

Avg plan cost$14.80

Part D spend $3.0M 1× spread, current vs floor

Class share

85%

of class CY24 spend

View profile →

Nalbuphine

2K Part D claims (CY24) · 186 beneficiaries · First FDA approval: 2004-12-31

2 generic mfrs

Low NADAC$4.32

→

Avg plan cost$4.32

Part D spend $532092 1× spread, current vs floor

Class share

15%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.